IMNR – The Immune Response Corporation Stock Guru found the new President of The Immune Response Corporation, Dr. Joseph F. O’Neill, on the road today, mid-way during his speaking tour. He took time between speaking engagements to share his opinion on IMNR’s value potential.
Dr. O’Neill believes the new direction of IMNR is creating investor value by focusing equally on MS and HIV/AIDS. He also stressed that the IMNR’s multiple sclerosis (MS) program may provide a platform in potentially new applications for autoimmune diseases including psoriasis and rheumatoid arthritis (RA).
“We have implemented a new clinical development strategy. We are going forward with our HIV/AIDS second generation vaccine which is based on Remune® but includes a Toll-like receptor (TLR) agonist and it is more potent. Additionally, we are investing in development of our MS vaccine.”
“Our value message is that we provide a rare opportunity for return on investment in that we have two Phase 2 products, each with the potential to become a multibillion dollar drug. In addition we believe we have great potential for advances in rheumatoid arthritis and psoriasis.”
Referring to the recent removal of rheumatoid arthritis (RA) drugs from the market Dr. O’Neill addressed the importance of providing new therapies in that area. “There is a tremendous medical vacuum in the field of rheumatoid arthritis and we will be in a position to make advances in these areas as well. After all, we are an established company building on twenty years of research.”
� Dr. O’Neill felt this was the most important element of his value message: “No where can you find a biotech company with twenty years of research experience under its belt with two Phase 2 products, each with multibillion dollar potential.”
Dr. O’Neill has a sincerity in his voice when he speaks. “We have the proven experience to navigate successfully in the regulatory environment. I think it’s clear that we know what we are doing and we are on an important path here. I want the scientific community and the investment community to understand the significance of what we’re doing. They don’t always have the time to come to us, that’s why I’m going to them.”
“I think the Incremental Advantage Report does a good job of sharing the value message of our company.”
Dr. O’Neill is committed to going anywhere and everywhere he can to deliver the message of The Immune Response Corporation.
To Access IncreMental Advantage Research Report CLICK HERE: http://www.pinksheets.com/quote/company_profile.jsp?symbol=IMNR.For additional information, please email ROI Group Associates at imnr@roiny.com or call Mike Dodge at 212-495-0744.
The Immune Response Corporation is focused on developing products to treat autoimmune and infectious diseases. The Company’s lead immune-based therapeutic product candidates are NeuroVax™ for the treatment of MS and IR103 for the treatment of HIV infection. Both of these therapies are in phase 2 clinical development and are designed to stimulate pathogen-specific immune responses aimed at slowing or halting the rate of disease progression.
�
NeuroVax™, which is based on the Company’s patented T-cell receptor ( TCR) peptide technology, has shown potential clinical value in the treatment of relapsing forms of MS. NeuroVax™ has been shown to stimulate strong, disease-specific cell-mediated immunity in nearly all patients treated and appears to work by enhancing levels of FOXP3+ Treg cells that are able to down regulate the activity of pathogenic T-cells that cause MS. Increasing scientific findings have associated diminished levels of FOXP3+ Treg cell responses with the pathogenesis and progression of MS and other autoimmune diseases such as rheumatoid arthritis (RA), psoriasis and Crohn disease.
�
IR103 is based on the Company’s patented whole-inactivated virus technology, co-invented by Jonas Salk and indicated to be safe and immunogenic in extensive clinical studies of Remune®, the Company’s first generation HIV product candidate. IR103 is a more potent formulation that combines its whole-inactivated antigen with a synthetic Toll-like receptor (TLR-9) agonist to generate enhanced HIV-specific immune responses. The Company is currently testing IR103 in two phase 2 clinical studies as a first-line treatment for drug-naive HIV-infected individuals not yet eligible for antiretroviral therapy according to current medical guidelines.
ABOUT THE IMMUNE RESPONSE CORPORATION The Immune Response Corporation (OTCBB: IMNR) is an immuno-pharmaceutical company focused on developing products to treat autoimmune and infectious diseases. Their lead immune-based therapeutic product candidates are NeuroVax™ for the treatment of multiple sclerosis (MS) and IR103 for the treatment of Human Immunodeficiency Virus (HIV). Both of these therapies are in Phase II clinical development and are designed to stimulate pathogen-specific immune responses aimed at slowing or halting the rate of disease progression. NeuroVax™, which is based IMNR’s patented T-cell receptor (TCR) peptide technology, has shown potential clinical value in the treatment of relapsing forms of MS. NeuroVax™ has been shown to stimulate strong disease specific cell mediated immunity in nearly all patients treated by enhancing levels of FOXP3+ T Regulatory (Treg) cells that are able to down regulate the activity of pathogenic T-cells that cause MS. Increasing scientific findings have associated diminished levels of FOXP3+ Treg cell responses with the pathogenesis and progression of MS and other autoimmune diseases such as rheumatoid arthritis (RA), psoriasis and Crohn’s disease. In addition to MS, IMNR has opened Investigational New Drug Applications (IND) with the U.S. Food and Drug Administration (FDA) for clinical evaluation of TCR peptide-based immune-based therapies for RA and psoriasis. IR103 is based on their patented whole-inactivated virus technology, co-invented by Dr. Jonas Salk and indicated to be safe and immunogenic in extensive clinical studies of REMUNE® , our first-generation HIV product candidate. IR103 is a more potent formulation that combines its whole-inactivated antigen with a synthetic Toll-like receptor (TLR-9) agonist to create enhanced HIV-specific immune responses. IMNR is currently testing IR103 in two Phase II clinical studies as a first-line treatment for drug-naïve HIV-infected individuals not yet eligible for antiretroviral therapy according to current medical guidelines. In early 2006 IMNR made a strategic decision to accelerate the development of IR103, rather than pursue a Phase III trial with REMUNE® . All of IMNR products are still in the development stage. IMNR has never had revenues from the sale of products. IMNR was founded in 1986.
Forward Looking Statement: This news release may contain forward-looking statements made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. While these statements are meant to convey to the public the company’s progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management’s opinion. While management believes such representation to be true and accurate based on the information available to the company, actual results may differ materially from those described. The company’s operations and business prospects are always subject to risks and uncertainties. Important facts that may cause actual results to differ are set forth in IMNR’s periodic filings with the U.S. Securities and Exchange Commission.Disclosure: Pentony Enterprises LLC was compensated $17,500 from ROI Group Associates Inc. for profile coverage. Pentony Enterprises LLC is not a registered investment advisers or broker/dealers. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.
� Disclosure: StockGuru.com is owned and operated by Pentony Enterprises LLC, 9555 Lebanon Road, Suite 103, Frisco, Texas 75035. Telephone: (214) 453-4258. Web: StockGuru.com. Email: Publisher@Stockguru.com.
Source: ROI Group Associates – Contact for more information
39 Broadway; NY, NY 10006
212.495.0744
mdodge@roiny.com
IMNR — Immune Response Corp. (The)
5931 Darwin Court
Carlsbad, CA 92008
Website: http://www.imnr.com
Phone: 760-431-7080�
